Your session is about to expire
← Back to Search
Microbiota Intervention for Parkinson's Disease (MICRO-PD Trial)
MICRO-PD Trial Summary
This trial will study whether the gut microbiome in people with Parkinson's disease (PD) correlates with their phenotypic characteristics, which can be improved with targeting the microbiome through dietary or therapeutic interventions.
MICRO-PD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMICRO-PD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 222 Patients • NCT01842581MICRO-PD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently taking levodopa for your condition and it is working well for you.You have Parkinson's disease.You have a long-term gastrointestinal (stomach and intestines) disease.You have taken antibiotics or probiotics recently.People with weakened immune systems.You have Parkinson's disease.You are currently taking levodopa for Parkinson's disease and your symptoms are not changing too much throughout the day.
- Group 1: Intervention
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there openings available for participants in this experiment?
"Affirmative, the details noted on clinicaltrials.gov indicate that this trial is now enrolling patients. It was first posted in mid-July 2019 and its most recent update came at the end of October 2022. This research initiative requires 86 volunteers to be recruited across a single location"
What is the total headcount of participants for this research?
"Affirmative. Per the clinicaltrials.gov platform, this medical research is presently seeking participants. The trial was first published on July 15th 2019 and most recently revised October 25th 2022. 86 individuals across 1 research centre must be recruited for the study to move forward."
What diseases or conditions may be managed with Rifaximin?
"Rifaximin is typically prescribed to manage the reoccurence of clostridium difficile infections, and can also be utilized in treating symptoms such as bacterial infections, irritable bowel syndrome (IBS), and diarrhea."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger